Skip to content

A real world study for butorphanol tartrate for peri operative analgesia and sedation in patients undergoing elective surgery for lower abdominal cancer

A real world study for butorphanol tartrate for peri operative analgesia and sedation in patients undergoing elective surgery for lower abdominal cancer

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000032588
Enrollment
Unknown
Registered
2020-05-03
Start date
2020-05-11
Completion date
Unknown
Last updated
2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lower abdominal cancer

Interventions

Case series:none

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-60 years who underwent selective surgery for tumors of the lower abdomen (colorectal cancer, urological tumor, gynecological tumor); 2. ASA level I-III; 3. Patients who use electronic controlled intravenous analgesia pump for postoperative analgesia, and the analgesic pump contains butorphanol tartrate; 4. Patients who used butorphanol tartrate for analgesia and sedation in perioperative period; 5. The patient or family member has signed the informed consent;

Exclusion criteria

Exclusion criteria: 1. Patients with opioid tolerance; 2. Patients who depend on nacodine; 3. Pregnant and lactating women; 4. Patients with mental illness or other reasons unable to cooperate; 5. Patients with central nervous system disease, craniocerebral injury or intracranial pressure rise before operation; 6. Patients with a history of chronic pain, long-term use of sedatives and antidepressants before operation; alcoholism; 7. Patients who take CNS stimulants or suffer from CNS disease or respiratory dysfunction at the same time; 8. Patients with myocardial infarction, ventricular dysfunction and coronary insufficiency; 9. Patients who participated in clinical studies of other drugs in recent three months; 10. The scope of operation involves diaphragm operation (reduction of ovarian cancer); 11. Patients with creatinine clearance rate < 80ml / min; 12. Patients younger than 18 years old.

Design outcomes

Primary

MeasureTime frame
VAS pain score;Ramsay Sedation score;Clavien Dindo grading system e;Recovery quality rating scale;

Countries

China

Contacts

Public ContactSun Zhirong

Fudan University Shanghai Cancer Center

sunrongsun@aliyun.com+86 18017317650

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026